Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162438 | 0.78 | CYP1A2 (1.00) | CYP1A2TP53ALDH1A1 | |
| SCHEMBL6215101 | 0.75 | PSEN1 (0.40) | CYP1A2 | |
| SCHEMBL15076813 | 0.75 | LMNA (0.36) | CYP1A2POLBL3MBTL1LMNAALDH1A1 | |
| SCHEMBL14388260 | 0.74 | CYP1A2 (0.67) | CYP1A2TP53CHRM5ADRA2CPOLB | |
| SCHEMBL4516096 | 0.73 | CYP1A2 (0.92) | CYP1A2TP53ALDH1A1 | |
| SCHEMBL3762079 | 0.73 | TP53 (0.56) | CYP1A2TP53HRH3POLBL3MBTL1 | |
| SCHEMBL25045014 | 0.72 | L3MBTL1 (0.42) | CYP1A2CHRM5ADRA2CPOLBL3MBTL1 | |
| SCHEMBL12738374 | 0.72 | KMT2A (0.43) | CYP1A2TP53CHRM5ADRA2CALDH1A1 | |
| SCHEMBL3744984 | 0.72 | CHRM5 (0.43) | CYP1A2CHRM5ADRA2CHRH3 | |
| SCHEMBL18539239 | 0.72 | CHRM5 (0.43) | CYP1A2CHRM5ADRA2CHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| EP-1476151-B1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORGANON NV (NL) | 2008-07-16 | — | — | EP | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
| EP-1476151-A1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Akzo Nobel N.V. (NL) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068220-A1 | 1-ARYLSULFONYL-3-SUBSTITUTED INDOLE AND INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | AKZO NOBEL N.V. (NL) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | TPH1, HTR1A, HTR1D | CYP1A2 353/4885TP53 3562/4885CHRM5 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.